7月28日，因塞特医疗盘中上涨5.24%，报125.455美元/股，成交额1.23亿美元。
消息面上，公司于盘前发布第二季度财报，业绩大幅超出市场预期。调整后每股收益3.09美元，远超市场一致预期的2.12美元，同比增长约97%；营收16.63亿美元，超预期的14.60亿美元。核心驱动来自湿疹药膏Opzelura相关医疗补助回扣问题与CMS达成和解，预计为全年净销售额增加3亿至3.1亿美元，同时确认2.46亿美元一次性非现金收益。第二季度净销售额同比增长40%，达14.9亿美元。公司已上调全年营收指引以反映和解协议影响。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.